Patent Covers Acclaim-3 Clinical Trials Combining REQORSA Gene Therapy with Genentech, Inc.'s Tecentriq®
The BIO International Convention Brings Together More Than 20,000 Biotech Industry Leaders From Around The World
Trop-2 H-scores Above 100 and PTEN H-scores Below 100 Correlated With Longer Progression Free Survival in Non-Small Cell Lung Cancer Patients
Pdx1/MafA Gene Therapy Reversed Hyperglycemia in Type 2 Diabetic Models Within Four Weeks
Strengthens Patent Estate and Expands Protection in Another Target Market
Pdx1/MafA Gene Therapy Reversed Hyperglycemia in Type 2 Diabetic Models Within Four Weeks
AUSTIN, Texas , April 22, 2026 /PRNewswire/ -- Genprex, Inc. ("Genprex" or the "Company") (NASDAQ: GNPX), a clinical-stage gene therapy company focused on developing life-changing therapies for...
Research on Biomarkers May Help Enrich Acclaim-1 and Acclaim-3 Lung Cancer Clinical Trials, Potentially Predicting Patient Response to REQORSA Treatment
TROP2 and PTEN Biomarkers May Predict Patient Response to Reqorsa ® Gene Therapy
Research Collaborators Identify Biomarkers that May Predict Patient Response to Reqorsa ® Gene Therapy